Announcements

Now covered by Medicare for favorable and intermediate risk prostate cancer

 

Who

The Oncotype DX Genomic Prostate Score Medicare coverage for favorable intermediate prostate cancer patients is defined as:

Gleason Score 3+3=6 (GG1*)

  • PSA <20
  • <cT1c‐cT2a

Gleason Score 3+3=6 (GG1)

  • PSA <10
  • <cT2b‐cT2c

Gleason Score 3+4=7 (GG2)

  • PSA <10
  • <cT1c‐cT2a

*GG = [Gleason] Grade Group

 

When

Effective October 2, 2017
 

GPS
Benefit

The Oncotype DX Genomic Prostate Score assay predicts prostate cancer death and metastasis1 within 10 years of receiving radical prostatectomy, as well as adverse pathology†2,3 to guide patient discussions and treatment decisions


†Adverse pathology is defined as Gleason Score 4+3 or higher and/or pT3+.

 

Medicare mandates Certification and Training. Are you registered?

  • If you've already completed CTR training, no further action is required for your patients to take advantage of this coverage
  • If not, please enroll now

Individualized and actionable risk assessment for better informed treatment decisions

  • PREDICTIVE OF PROSTATE CANCER DEATH and METASTASIS within 10 years of receiving radical prostatectomy1
  • PREDICTIVE OF ADVERSE PATHOLOGY,2,3 the most immediate and actionable endpoint when making treatment decisions
  • DEVELOPED, VALIDATED AND STUDIED in over 4,000 patients1-8
  • MEDICARE-COVERAGE for use in patients with NCCN very low- and low-risk prostate cancer, and favorable intermediate
  • INCLUDED IN NCCN GUIDELINES® as an option to help guide management decisions9
REFERENCES

1. Van Den Eeden et al. AUA 2017.
2. Klein et al. Eur Urol. 2014.
3. Cullen et al. Eur Urol. 2014.
4. Bonham et al. USCAP. 2016.
5. Eure et al. AUA 2017.
6. Badani et al. Urol Pract. 2015.
7. Dall’Era et al. Urol Pract. 2015.
8. Knezevic et al. BMC Genomics. 2013.
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology®. Version 1.2017. Available at: www.nccn.org. Accessed January 10, 2017.


NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product.

Do You Have a Question?

Contact Us

Do you need CTR training?

To qualify your patients for Medicare coverage, you must be enrolled in Medicare's Certification and Training Registry. It's quick and easy.

Enroll Now

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™